# Effects of Henagliflozin Proline and Metformin XR on Body Composition in Geriatric Patients With Newly Diagnosed T2DM

Study · id `cardio:ct-nct07323381` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07323381](<https://clinicaltrials.gov/study/NCT07323381>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07323381

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 116 participants.

## Technical summary

Registry record NCT07323381. Randomized; no masking; primary purpose treatment. Start 2025-12-30 (anticipated); primary completion 2027-09-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 116 participants (planned count; ClinicalTrials.gov record NCT07323381, source copy `cardio:ctgov-nct07323381-2026-01-07`, retrieved 2026-10-26)
- Planned start: 2025-12-30 (anticipated) (ClinicalTrials.gov record NCT07323381, source copy `cardio:ctgov-nct07323381-2026-01-07`, retrieved 2026-10-26)
- Primary completion: 2027-09-30 (anticipated) (ClinicalTrials.gov record NCT07323381, source copy `cardio:ctgov-nct07323381-2026-01-07`, retrieved 2026-10-26)
- Completion: 2027-09-30 (anticipated) (ClinicalTrials.gov record NCT07323381, source copy `cardio:ctgov-nct07323381-2026-01-07`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07323381-2026-01-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effects of Henagliflozin Proline and Metformin XR on Body Composition in Geriatric Patients With Newly Diagnosed T2DM
- Acronym: HABIT-GEMs
- Condition: Diabetes Type 2
- Intervention (Drug): Henagliflozin Proline Tablets treatment
- Intervention (Drug): Metformin XR treatment
- Lead sponsor: Bin Lu
- Lead sponsor class: OTHER
- Collaborator: Shanxi Provincial People's Hospital
- Collaborator class: OTHER\_GOV
- Collaborator: Zhongnan Hospital
- Collaborator class: OTHER
- Collaborator: Second Affiliated Hospital of Soochow University
- Collaborator class: OTHER
- Collaborator: The Second Affiliated Hospital of Shandong First Medical University
- Collaborator class: OTHER
- Collaborator: Fifth Affiliated Hospital, Sun Yat-Sen University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as a collaborator: Zhongnan Hospital (`cardio:org-zhongnan-hospital`)
- Registry lists this organization as a collaborator: Second Affiliated Hospital of Soochow University (`cardio:org-second-affiliated-hospital-of-soochow-university`)

## Provenance

Content hash: c5e63c11bfb3efeb151014cb193881bfb9de8904d952572154fbc111019e682b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
